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Abstract
Background—Kidney transplant recipients are at increased risk for adverse safety events related 
to their reduced renal function and many medications.
Methods—We determined the incidence of adverse safety events based on previously defined 
Agency for Healthcare and Research Quality (AHRQ) ICD-9 code-derived patient safety 
indicators (PSI) in the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial 
participants who had a hospitalization stratified by tertiles of estimated glomerular filtration rate. 
We also examined the frequency of Micromedex defined two precautionary drug-drug 
interactions, and two medications whose use may be contraindicated due to reduced GFR from the 
FAVORIT trial Medication Thesaurus at baseline, and annually among 4110 participants. Logistic 
regression was used to examine the relationship between patient safety events and baseline 
demographic and clinical variables at a participant level. Event rates were estimated at participant 
and visit levels.
Results—Of the 2514 patients with a hospitalization, 978 (38.9%) experienced an AHRQ PSI. 
Factors which were associated with more common AHRQ PSI included: US location, history of 
cardiovascular disease or diabetes, and lower tertile of estimated GFR. At a participant level, 2524 
of the 4110 participants (61.4%) were taking a CNI and a statin, 378 (9.2%) were taking 
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azathioprine and an ACE inhibitor, 171 (12.9%) were taking a sulfonylurea ), 45 (3.4%) were 
taking metformin despite a baseline GFR below 40 ml/min/1.73m2.
Conclusions—We conclude that patient safety events are not uncommon in kidney transplant 
recipients. Careful monitoring is necessary to prevent adverse outcomes.
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Introduction
Patients with chronic kidney disease (CKD) are at increased risk for adverse safety events 
related to their care 1-3 however little work has been done to determine the impact of these 
safety events on CKD outcomes. This is particularly relevant in kidney transplant recipients 
who often have reduced estimated glomerular filtration rate (GFR) where medication dosage 
adjustment may be required, and there is increased risk of drug: drug interactions 4. 
Moreover it remains unanswered how precautionary statements issued by Micromedex 
about potential drug-drug interactions in transplant recipients translate into patient safety 
events in this population. This study aimed to identify the frequency of general patient safety 
events as determined by hospital-based ICD-9 codes, as well as the frequency of usage of 
commonly administered medications which are ill-advised in individuals with reduced GFR. 
We postulated that a high frequency of published precautionary drug interactions would be 
present as part of this population’s usual medical management profile, and questioned 
whether these exposures may be associated with adverse events.
Results
Patient characteristics
Participant characteristics are shown in Table 1. The mean age was 52 years with a 
predominance of males (63%) and approximately 25% non-white race. The majority of the 
participants (73%) were from the United States, but there was substantial representation 
from Brazil (15%), and Canada (12%). The graft vintage was on average five years. Many 
of the patients had a history of cardiovascular disease (20%), diabetes mellitus (40%), and 
hypertension (92%). Only 11% were current smokers and mean baseline GFR was 49 
ml/min/1.73m2. Follow-up ranged from 0-6.8 years yielding a mean of 4.0 +/− 1.5 years. 
During follow-up, 62% of the participants were hospitalized at least once, and accrued a 
total of 7939 hospitalizations.
Overall safety events
There were a substantial number (39%) of participants who were hospitalized with AHRQ 
PSI (Table 2). Overall, about 20% of all hospitalizations events were considered as PSI 
events. It is important to note, that patients in the lowest tertile of estimated GFR, 
experienced more AHRQ PSI at the participant level and hospitalizations considered as PSI 
events. The rates for AHRQ PSI at the three tertiles of GFR were significantly different 
from each other for both participant level (p<.0001) and hospitalizations (p=.0004).
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There was frequent use of statins with CNI (61% at the participant level) as well as 
sulfonylureas (13%) and metformin (4%) at the participant level) (Table 3). Patients with the 
lowest tertile of GFR experienced no more participant level and visit level patient safety 
events, while receiving metformin or sulfonylurea drugs’ compared to those patients in the 
higher GFR tertiles.
Demographics and clinic characteristics: AHRQ Patient Safety Indicators
Overall, patients with diabetes or cardiovascular disease (CVD) were more likely to 
experience AHRQ PSI at the patient level (Table 4). Interestingly, transplant patients from 
Canada and Brazil were less likely to experience patient level AHRQ events compared to 
patients from the US. Also, patients with higher GFR were less likely to experience events. 
We also evaluated GFR as a continuous variable, rather than as tertiles, and observed that 
for each 1ml / min / 1.73 m2 increase in estimated GFR that the odds ratio for an event was 
0.99 (0.98-0.99), p<.001.
As seen in Table 5, the incidence of myopathy was low and was not associated with the use 
of a CNI and a statin. The use of an ACE inhibitor with azathioprine was associated with an 
increased risk of shock/sepsis, p=0.04. Patients in the lowest tertile of GFR taking a 
sulfonylurea or metformin experienced more diabetic ketoacidosis/coma than those patients 
in the middle or higher tertiles of GFR. On the other hand, the risk of hypoglycemia was 
higher in the middle tertiles of GFR.
Drug interaction: CNI and a statin
Participants of older age or with known CVD were more likely to receive a combination of a 
CNI and a statin (SDC, Table 1). Interestingly patients of African heritage were less likely to 
receive both, as well as were individuals from Brazil. Canadians were more likely to receive 
a statin and a CNI compared to the US participants. Likewise, patients with history of 
diabetes, or who were overweight, were more likely to receive a statin and a CNI, as were 
patients with higher baseline GFR.
Drug interaction: Azathioprine and an ACE inhibitor
The combination of azathioprine and an ACE inhibitor was more common in Brazil, in 
patients with older graft vintage, and in current smokers (SDC, Table 2). This drug 
combination was less common in Canada compared to the US, in patients with lower 
baseline GFR, as well as those with hypertension.
Potential Safety events: Diabetic Patients on a sulfonylurea
Older participants, patients of African heritage, and higher BMI were more likely to receive 
a sulfonylurea with a reduced baseline GFR. This was also more commonly seen in Canada, 
compared to US or Brazil (SDC, Table 3). Not surprisingly, history of diabetes and 
overweight patients were more likely to receive a sulfonylurea.(SDC, Table 3).
Potential Safety events: Diabetic Patients on Metformin
Older patients, those patients with higher BMI, and non-US patients were commonly 
prescribed metformin. Males were less likely to receive metformin. Patients with a higher 
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GFR were more likely to receive metformin compared to those with a lower GFR. (SDC, 
Table 4).
Discussion
Recipients of kidney transplants are at increased risk for adverse safety events related to the 
many medications that they receive for their immunosuppression and medical comorbidity. 
Moreover, many of these patients have estimated GFR in the lower tertile, <40 ml/min/1.73 
m2. Little information exists in the literature as to the relationship between medication 
misuse, drug: drug interactions, and adverse outcomes. To our knowledge, this is the first 
report which has examined the frequency of Micromedex precautionary drug interactions 
and the use of medications which may be contraindicated in kidney transplant patients due 
to reduced estimated GFR. Herein, we describe that patient safety exposures are not 
uncommon, and some exposures may put patients at much greater risk for adverse outcomes, 
whereas others do not.
Overall, we noted that about 20% of all hospitalizations were considered as PSI events. Not 
surprisingly, patients with reduced estimated GFR, diabetes or CVD were more likely to 
experience AHRQ PSI likely related to greater use of medications for treatment of these 
comorbidities. Higher GFR was associated with reduced risk of PSI events, as were non-US 
patients. Interestingly, the lower risk of PSI in non-US patients was evident despite greater 
use of statins, sulfonylureas, and metformin in Canadian patients. With the expanding circle 
of health care providers involved in the clinical care of kidney transplant recipients, the 
opportunity for medication misuse and patient safety events is substantial. In addition, the 
large number of newer medications for immunosuppression, infection, and medical co-
morbidities places an increasing burden on prescribers to be sure about medication 
interactions (especially with the immunosuppression medications) and use in patients with 
reduced renal function. Our observations in this trial provide important perspectives in this 
regard and indicate the need for continued surveillance and better strategies to facilitate 
education for both patients and healthcare providers.
We specifically chose to examine two common Micromedex defined precautionary drug: 
drug interactions: those patients taking a CNI and a statin and those taking azathioprine and 
an ACE inhibitor. CNI alter statin metabolism and may enhance their overall effect, but also 
increase their risk of inducing myopathy and possibly even rhabdomyolysis12-14. Although 
statins are of great use in reducing the risk of cardiovascular events in both the general 
population, as well as in the transplant population 17, 18, the therapeutic index has been 
questioned by some. Jardine 19 has noted that there are more myopathic events in patients 
receiving statins with cyclosporine. In the FAVORIT trial, more than 25% of patients were 
receiving both drugs which resulted in comparable visit level event and non-event 
exposures. Overall, there were only 44 AHRQ PSI myopathy events, which is remarkably 
low considering the exposure. Although there was a trend toward more patients receiving a 
CNI and a statin to experience myopathy, due to the low event frequency, this was not 
statistically significant. These observations would suggest that the concern of clinically 
significant myopathy requiring hospitalization with the concomitant use of a CNI and a 
statin is quite low 15, 16and is more than offset by the beneficial effects of statins on 
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cardiovascular risk in renal transplant recipients. Nonetheless, caution is required, especially 
with the use of higher doses of statins.
Likewise, we examined the percentage of patients receiving both azathioprine, and an ACE 
inhibitor, which is also listed as “medication error” by Micromedex. This combination may 
increase the risk of leukopenia and anemia. Although not well recognized in current 
literature due to the diminished use of azathioprine, there are many patients with older grafts 
who receive both medications. In our cohort, 378 patients were receiving both, albeit with a 
low visit level event to non-event ratio. There did not appear to be a correlation between 
taking these two drugs and AHRQ hospitalization events of shock or sepsis, with only 316 
total events, of which only 19 occurred in patients taking both drugs. This would indicate 
that this interaction is unlikely to be of clinical concern. Unfortunately, we did not capture 
transfusion events in our data set to see if the use of the two drugs influenced the need for 
transfusions. Interestingly, mycophenolate mofetil and mycophenolic acid are the two 
antimetabolites which are most commonly used in transplantation today, yet are not listed in 
Micromedex as a “medication error” with a renin-angiotensin system blocking drug.
The use of sulfonylureas, particularly glyburide, and metformin in kidney transplant patients 
may be more complicated, especially in those patients with lower GFR 8-11 Although the 
FAVORIT medication thesaurus would not allow distinctions between type of sulfonylureas, 
it was evident that the use of these drugs, even in the lower tertile of estimated GFR, was not 
associated with an increased risk of patient safety events. Since the FAVORIT study start 
was in 2005, it is likely that many of the patients were receiving older sulfonylureas such as 
glyburide, which does require dosage adjustment in patients with reduced renal function 9. 
Thus, there were a sizeable number of visit level event exposures during the course of the 
FAVORIT trial. This was of particular concern, as it has been described in literature that 
hypoglycemia and lactic acidosis can occur with use of these types of oral anti-diabetic 
medications in patients with reduced GFR11. Although we could not distinguish between the 
types of acidosis based on the AHRQ ICD-9 codes, it was apparent that diabetic 
ketoacidosis/coma was nearly three times more common in patients taking these drugs, as 
compared to those not taking them, and occurred more frequently in patients in the lowest 
tertile of estimated GFR. Hypoglycemia can occur in patients taking these drugs, which 
would necessitate some caution, with the use of these drugs in patients with reduced 
estimated GFR. Moreover, a study in diabetic patients with chronic kidney disease 
demonstrated increased one day mortality in those individuals reduced GFR experiencing 
hypoglycemia 20. However, we did not observe an increased risk of hypoglycemia with the 
use of these drugs in our lowest estimated GFR tertile group.
In summary, these descriptive data provide the first opportunity to examine the frequency of 
precautionary medication exposures in a large cohort of prevalent kidney transplant 
recipients from three different countries. This data set also provides an opportunity to 
examine between country differences, as well as clinical factors and patient characteristics 
which predispose to these exposures. Our results indicate that there is a high frequency of 
published (Micromedex) precautionary drug interactions as part of the usual pharmacy 
profile in kidney transplant patients. Our data suggests that some of these precautionary 
Weir et al. Page 5













statements are of less clinical relevance than previously thought. But, others are of 
substantial concern.
The strength of our observations stems from the well described cohort of transplant 
recipients from diverse backgrounds, and the detailed efforts to capture all hospitalization 
data. More than 4000 participants were followed for more than four years. The limitations of 
our observations are related to the categorization of drugs within the Medication Thesaurus, 
which frequently lumped classes of medications together for simplicity, the lack of notation 
of dose, the categorization of ICD-9 codes, and the care and the completeness of the coding 
process, and the limitation of relying only on hospitalization data, which represents only a 
small portion of general renal transplant recipient care. Further, the opportunity to examine 
individual medications of concern such as glyburide, among the sulfonylureas, was not 
possible. In addition, other types of medication, such as potassium-sparing diuretics, may 
put patients at greater risk for adverse outcomes such as potassium sparing diuretics, 
however our Medication Thesaurus was not designed to examine all of the many individual 
medications that were used in our patients. Our results also underscore the difficulties in 
identifying relevant drug interactions and safety events even in the context of a prospective 
cohort study.
Our relatively limited description of exposures in renal transplant recipients likely only 
scratches the surface of potential adverse events in this population. The frequency of these 
events is sufficient to raise concern about our current clinical practice and how we may best 
protect our patients from patient safety events related to misuse of medications in this at risk 
population.
Methods
The study was conducted using data obtained from the Folic Acid for Vascular Outcome 
Reduction in Transplant (FAVORIT) trial, a multi-center, multi-country, double-blind, 
randomized controlled clinical trial conducted to determine whether lowering homocysteine 
levels with vitamin therapy would reduce the rate of pooled atherosclerotic cardiovascular 
disease outcomes in 4110 kidney transplant recipients with mean follow-up of four years 5. 
Details of the study design have been previously published 5. The trial received approval 
from institutional review boards or ethical boards from all thirty clinical sites.
Study participants
Kidney transplant recipients between the ages of 35 and 75 years who were at least 6 months 
post-transplant were screened for eligibility. Study criteria required: elevated homocysteine 
levels and stable kidney function with an estimated GFR >30 ml/min/1.73m2 through July 7, 
2005, after which the cut-point for women was reduced to >25 ml/min/1.73m2. Estimated 
GFR utilized for screening was the Cockroft-Gault formula. Baseline data utilized the CKD-
EPI formula to calculate estimated GFR 6. Race and ethnicity were self-determined.
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The trial enrolled participants between August 2002 and January 2007. Follow-up contacts 
occurred every six months through January 2010 to obtain study-related outcomes through 
June 2009.
Safety Events Ascertainment
We initially evaluated the incidence of adverse safety events based on Agency for 
Healthcare and Research Quality (AHRQ) 7 patient safety indicators (PSI) in the FAVORIT 
participants who had a hospitalization 7 stratified by estimated GFR. For the determination 
of ICD-9 derived safety events, the AHRQ was integrated with FAVORIT hospitalization 
ICD-9 data.
Next, we also examined the frequency of use of sulfonylureas (particularly glyburide) and of 
metformin in kidney transplant recipients stratified by estimated GFR due to the increased 
reported risk of hypoglycemia and lactic acidosis, respectively 8-11. Information on the 
specific sulfonylurea type used was not available in this dataset.
Lastly, we focused on the frequency of two Micromedex precautionary drug-drug 
interactions including: the use of statins and calcineurin inhibitors (CNI), and angiotensin-
converting enzyme (ACE) inhibitors with azathioprine. These two drug-drug interactions 
were chosen due to the increased risk of myopathy and rhabdomyolysis with concurrent use 
of CNI 12-14, and the greater reported risk of anemia and leukopenia when ACE inhibitors 
are combined with azathioprine. Our medication thesaurus did not provide distinction about 
the type of medication, nor the dose15, 16.
Statistical analysis
The use of medication at a participant level was determined at baseline and at each follow-
up visit. A participant was recorded as having used the medication if he used it at least on 
one occasion. Logistic regression was utilized to examine the relationship between outcome 
variables and a variety of baseline demographic and clinical variables at a participant level. 
Data at the visit level for each patient were tabulated as the number of visits with events out 
of the total number of visits for that patient. The rates at the visit level were estimated using 
logistic regression with over dispersion. Presence of an ICD-9 code was compared in groups 
with and without the medication exposure, where exposure was determined based on the 
follow-up visit preceding the occurrence of the ICD-9 event. Patients were stratified by 
estimated GFR (ml/min/1.73m2) into tertiles: low (mean 31.02, 9.5-39.1), middle (mean 
46.32, 39.2-53.8) and high (mean 68.6, 53.9-131.8). Analyses were performed at both the 
patient, and visit level. All analyses were performed using SAS statistical software (SAS 
Institute Inc., SAS® 9.2, Cary, NC, USA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Baseline Characteristics of Study Participants
Characteristics n (%) or mean ± SD(n=4110)
Age in years 52 ± 9.4
Female sex 1528 (37.2)
Nonwhite race 998 (24.5)
Country
  Brazil 612 (14.9)
  Canada 498 (12.1)
  United States 3000 (73.0)
Graft vintage in years 5 ± 5.0
History of CVD 820 (20.0)
History of diabetes mellitus 1663 (40.5)
Hypertension 3778 (92.0)
Body mass index (kg/m2) 29 ± 6.2
Current Smoker 451 (11.1)
Baseline creatinine (μmol/L) 1.7 ± 0.6
Baseline eGFR (mL/min per 1.73 m2) 48.9 ± 17.7
Baseline CKD Stage
  Stage 1 (eGFR 90 mL/min per 1.73 m2) 115 (2.9)
  Stage 2 (eGFR 60-89 mL/min per 1.73 m2) 822 (20.4)
  Stage 3 (eGFR 30-59 mL/min per 1.73 m2) 2571 (63.9)
  Stage 4 (eGFR 15-29 mL/min per 1.73 m2) 507 (12.6)
  Stage 5 (eGFR <15 mL/min per 1.73 m2) 10 (0.3)
Abbreviations: CVD = Cardiovascular Disease
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Table 2
Agency for Healthcare Research Quality (AHRQ) Patient Safety Indicators (PSI) stratified by tertile of GFR
AHRQ Patent Safety Indicator (PSI) Present
Yes No
N % N %
Participant Observed Rate 978 38.9 1536 61.1
Low tertile GFR 406 45.2 492 54.8
Middle tertile GFR 290 36.8 497 63.2
High tertile GFR 255 33.5 507 66.5
Hospitalizations Observed Rate 1606 20.2 6333 79.8
Low tertile GFR 663 22.4 2334 77.6
Middle tertile GFR 468 19.7 1865 80.3
High tertile GFR 423 17.5 1905 82.5
p-value <.0001 for participant observed differences in rates for GFR, P value = 0.004 for hospitalization observed differences in rate for 
GFR. Based on chi-square test GFR=estimated glomerular filtration rate
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Table 3
Overall Safety Events in FAVORIT Participants
Participant Visit 
+
N % N %
Drug Interaction
CNI and Statin 2524/4110 61.4 7898/16327 47.4
AZA and ACEI 378/4110 9.2 1036/16327 6.3
Metformin Use Stratified by GFR tertile Participant* Visit**
Low tertile GFR 45/1325 3.4 104/5081 2.0
Middle tertile GFR 54/1322 4.1 124/5330 2.5
High tertile GFR 65/1359 4.7 140/5496 2.6
Sulfonyluree use Stratified by GFR tertile Participant*** Visit****
Low tertile GFR 171/1325 12.9 388/5081 7.6
Middle tertile GFR 182/1322 13.8 429/5337 7.9
High tertile GFR 180/1369 13.1 425/5496 7.5
CNI=calcineurin inhibitor, AZA=azathioprine, ACEI=angiotensin-converting enzyme inhibitor, GFR=estimated glomerular filtration rate
+
Rates computed using proc logistic scale=Williams.
*
p value = 0.08,
**
p value = 0.09,
***
p value = 0.80,
****
p value = 0.72
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Table 4
Demographics and Clinical Characteristics: AHRQ Patient Safety Indicators
Characteristic Likelihood Estimate 95% Confidence Interval
Age (years) quartile
  <44 (Reference) 1.00
  45-54 vs. <44 0.87 (0.68-1.10)
  55-64 vs. <44 0.95 (0.74-1.22)




African heritage 1.05 (0.84-1.32)
Other 0.93 (0.64-1.36)
Location
  US (Reference) 1.00
  Canadian 0.41 (0.29-0.57)*
  Brazil 0.18 (0.13-0.26)*
No history of CVD 1.00
History of CVD 1.39 (1.13-1.71)*
No history of diabetes 1.00
History of diabetes 1.25 (1.04-1.49)**
Smoking
  Never smoker (Reference) 1.00
  Current smoker 1.25 (0.94-1.66)
  Ever smoker 1.13 (0.93-1.36)
BMI (kg/m2) tertile
  Lowest (15.8-25.8) (Reference) 1.00
  Middle (25.9-30.6) 1.14 (0.91.-1.42)
  Highest (30.7-57.5) 1.14 (0.91-1.41)
Graft Vintage tertile
  Lowest (0.3-2.2) (Reference) 1.00
  Middle (2.3-6.0) 0.96 (0.78-1.19)
  Highest (6.1-46.2) 1.01 (0.82-1.25)
No prevalent hypertension 1.00
Prevalent hypertension 0.94 (0.66-1.35)
Glomerular Filtration Rate tertile
  Lowest (9.5-39.1) (Reference) 1.00
  Middle (39.2-53.8) 0.69 (0.56-0.85)*
  Highest (53.9-131.8) 0.59 (0.48-0.73)*
Abbreviations: AHRQ=Agency for Healthcare and Research Quality, US=United States, CVD=cardiovascular disease, BMI=body mass index
*
p-value < 0.01,













Weir et al. Page 14
**
p-value <0.05.
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Table 5
Medication Administration and Agency for Healthcare and Research Quality ICD-9 code Derived Patient 
Safety Indicator Events
Event Participants taking both CNI and Statin
Yes No
N % N % p-value
Myopathy Yes 30 1 14 1 0.35
No 2494 99 1572 99
Participants taking both ACEI and AZA
Yes No
N % N % p-value
Shock/Sepsis Yes 19 5 297 8 0.04
No 359 95 3435 92
Participants taking Sulfonylurea or Metformin
stratified by tertile of GFR
Yes No
N % N % p value
Diabetic Ketoacidosis/Coma*
Low tertile GFR.........Yes 70 34.5 133 65.5 <.0001
.................................... No 207 18.5 915 81.5
Middle tertile GFR......Yes 70 32.9 171 15.4 <.0001
.................................... No 143 67.1 938 84.6
High tertile GFR........Yes 61 28.1 197 17.1 .0001
.................................... No 156 71.9 955 82.9
Hypoqlycemia**
Low tertile GFR.........Yes 6 3.0 32 2.8 0.83
.................................... No 197 97.0 1090 97.2
Middle tertile GFR ..Yes 10 4.7 13 1.2 0.002
.................................... No 203 95.3 1096 98.8
High tertile GFR..... ..Yes 8 3.7 18 1.6 0.052
.................................... No 209 96.3 1134 98.4
CNI – calcineurin inhibitor, AZA = azathioprine, ACEI = angiotensin-converting enzyme inhibitor GFR=estimated glomerular filtration 
rate.
*
p value = 0.34
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